The Latest Analyst Ratings for Ascendis Pharma
Portfolio Pulse from Benzinga Insights
In the last 3 months, 8 analysts have offered 12-month price targets for Ascendis Pharma (NASDAQ:ASND), with an average price target of $129.25, down 6.92% from the previous average of $138.86.
June 01, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ascendis Pharma's average 12-month price target from 8 analysts is $129.25, down 6.92% from the previous average of $138.86.
The average 12-month price target for Ascendis Pharma has decreased by 6.92% from the previous average, indicating a potential change in analysts' outlook on the stock. However, the overall ratings remain mixed with 2 bullish, 3 somewhat bullish, and 3 indifferent ratings, suggesting a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100